Motus GI Holdings (DB:7M4) - Stock Price, News & Analysis

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

7M4 Stock Overview

Operates as a medical technology company in the United States.

About the company

7M4 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Rewards

Revenue is forecast to grow 142.15% per year

Earnings have grown 5.1% per year over the past 5 years

Risk Analysis

Makes less than USD$1m in revenue ($364K)

Shares are highly illiquid

Negative shareholders equity

Shareholders have been substantially diluted in the past year

+ 3 more risks

Motus GI Holdings, Inc. Competitors

MagForce

XTRA:MF6

€3.6m

elexxion

XTRA:E8X

€3.1m

MagForce

DB:MF6

€366.9k

Audientes

DB:AUG

€6.9m

Price History & Performance

Summary of all time highs, changes and price drops for Motus GI Holdings
Historical stock prices
Current Share Price	US$8.25
52 Week High	US$15.90
52 Week Low	US$5.50
Beta	1.49
11 Month Change	0%
3 Month Change	6.59%
1 Year Change	-38.20%
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	-98.44%

Recent updates

Shareholder Returns

	7M4	DE Medical Equipment	DE Market
7D	0%	-3.7%	-1.9%
1Y	-38.2%	6.6%	12.3%

Return vs Industry: 7M4 underperformed the German Medical Equipment industry which returned -0.6% over the past year.

Return vs Market: 7M4 underperformed the German Market which returned 0.1% over the past year.

Price Volatility

Is 7M4's price volatile compared to industry and market?
7M4 volatility
7M4 Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	5.4%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	10.8%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: 7M4's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine 7M4's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2008	46	Mark Pomeranz	www.motusgi.com

Motus GI Holdings, Inc. operates as a medical technology company in the United States. It develops Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during the colonoscopy and facilitates upper gastrointestinal endoscopy procedures. The company was formerly known as Eight-Ten Merger Corp. and changed its name to Motus GI Holdings, Inc. in November 2016.

Motus GI Holdings, Inc. Fundamentals Summary

How do Motus GI Holdings's earnings and revenue compare to its market cap?
7M4 fundamental statistics
Market cap	€1.42m
Earnings (TTM)	-€12.69m
Revenue (TTM)	€336.08k

4.1x

P/S Ratio

-0.1x

P/E Ratio

Is 7M4 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
7M4 income statement (TTM)
Revenue	US$364.00k
Cost of Revenue	US$754.00k
Gross Profit	-US$390.00k
Other Expenses	US$13.35m
Earnings	-US$13.74m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-8.88
Gross Margin	-107.14%
Net Profit Margin	-3,775.82%
Debt/Equity Ratio	-370.7%

How did 7M4 perform over the long term?

See historical performance and comparison

This company listing is no longer active

7M4 Stock Overview

Rewards

Risk Analysis

Motus GI Holdings, Inc. Competitors

XTRA:MF6

€3.6m

XTRA:E8X

€3.1m

DB:MF6

€366.9k

DB:AUG

€6.9m

Price History & Performance

Recent News & Updates

Motus GI Holdings, Inc.(OTCPK:MOTS) dropped from S&P TMI Index

Motus GI Holdings, Inc.(OTCPK:MOTS) dropped from NASDAQ Composite Index

Motus GI Holdings Receive Non-Compliance Letter from Nasdaq Related to Listing Rule 5550(a)(2)

Motus GI Holdings, Inc. Publishes Positive Results from A European Study of the Second Generation Pure-Vu System in Improving Visualization for Colonoscopy in Patients with A History of Poor Bowel Preparation

Motus GI Holdings, Inc. Announces First Upper GI Patient Procedure for FDA Cleared Pure-Vu®? EVS Gastro

Motus GI Holdings, Inc. Receives Fda Clearance to Commercialize Pure-Vu Evs Gastro and Gen 4 Colon

Recent updates

Motus GI Holdings, Inc.(OTCPK:MOTS) dropped from S&P TMI Index

Motus GI Holdings, Inc.(OTCPK:MOTS) dropped from NASDAQ Composite Index

Motus GI Holdings Receive Non-Compliance Letter from Nasdaq Related to Listing Rule 5550(a)(2)

Motus GI Holdings, Inc. Publishes Positive Results from A European Study of the Second Generation Pure-Vu System in Improving Visualization for Colonoscopy in Patients with A History of Poor Bowel Preparation

Motus GI Holdings, Inc. Announces First Upper GI Patient Procedure for FDA Cleared Pure-Vu®? EVS Gastro

Motus GI Holdings, Inc. Receives Fda Clearance to Commercialize Pure-Vu Evs Gastro and Gen 4 Colon

Motus GI Holdings Announces Update on Non-Compliance with Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market

Motus GI Holdings, Inc. Announces Executive Changes

New major risk - Financial position

Second quarter 2023 earnings released: US$0.40 loss per share (vs US$1.86 loss in 2Q 2022)

Motus GI Holdings, Inc. Receives Approval from the Israeli Ministry of Health to Initiate Commercial Sales of Its Pure-Vu® EVS System

Motus GI Holdings, Inc., Annual General Meeting, Sep 21, 2023

Shervin Korangy Resigns from the Board of Directors of Motus GI Holdings, Inc

Motus GI Holdings Provides Shareholder's Equity Compliance Update

Motus GI Announces Pure-Vu Gen 4 Gastro and Colon System Featured at 9th IECED Live Endoscopy Course 2023 At the Pentax Learning Center

Motus GI Holdings, Inc. Announces Executive Changes

Motus GI Holdings, Inc. announced that it expects to receive $3.5 million in funding

Motus GI Holdings, Inc. Completes First Clinical Evaluation of New Pure-Vu(R) Gastro in Upper Gastrointestinal Procedures to Support Fda Submission

First quarter 2023 earnings released: US$0.92 loss per share (vs US$1.86 loss in 1Q 2022)

Motus GI Holdings Receives Non-Compliance Notice From Nasdaq

Motus GI Holdings, Inc. Announces Improvement of Pure-Vu® EVS System for Use in Upper Gastrointestinal (GI) Bleeding Procedures Following Successful Pre-Clinical Tests

Insufficient new directors

Motus GI Holdings, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Second quarter 2022 earnings released: US$1.86 loss per share (vs US$1.99 loss in 2Q 2021)

Motus GI Regains Compliance with Nasdaq Minimum Bid Price Requirement

Motus GI Holdings, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Motus GI Holdings Announces Positive Topline Data from EU Study of the Pure-Vu System in Hard-to-Prepare Patients Presented at Digestive Disease Week 2022

Motus GI Holdings Announces Positive Topline Data from EU Study of the Pure-Vu System in Hard-to-Prepare Patients Presented at Digestive Disease Week 2022

Motus GI Holdings, Inc., Annual General Meeting, Jun 30, 2022

First quarter 2022 earnings released: US$0.093 loss per share (vs US$0.26 loss in 1Q 2021)

Insufficient new directors

Motus GI Completes Enrollment in the European Union Feasibility Study of the Pure-Vu System as a New Method for Bowel Cleansing in Patients with a History of Poor Bowel Preparation

Full year 2021 earnings released: US$0.54 loss per share (vs US$0.60 loss in FY 2020)

Motus GI Grants 180-Day Extension to Meet NASDAQ Minimum Bid Price Requirement

Motus GI Holdings, Inc. Receives FDA Clearance to Market the Pure-Vu® EVS System

Third quarter 2021 earnings released: US$0.10 loss per share (vs US$0.13 loss in 3Q 2020)

Insufficient new directors

Independent Director Samuel Nussbaum has left the company

Second quarter 2021 earnings released: US$0.099 loss per share (vs US$0.15 loss in 2Q 2020)

Motus GI Announces First Patients Enrolled in the European Union Feasibility Study of the Pure-Vu® System as a New Method for Bowel Cleansing in Patients With a History of Poor Bowel Preparation

First quarter 2021 earnings released: US$0.26 loss per share (vs US$0.23 loss in 1Q 2020)

Forecast to breakeven in 2025

Motus Gi Holdings, Inc. Announces Publication of A Pure-Vu System® Cost Effectiveness Analysis in the Journal of Cost Effectiveness and Resource

Motus GI Receives FDA Clearance to Market the Pure-Vu® System for Upper GI Endoscopy

Shareholder Returns

Price Volatility

About the Company

Motus GI Holdings, Inc. Fundamentals Summary

4.1x

-0.1x

Earnings & Revenue